SCHEMBL470994

SCHEMBL470994

CC(C)OCCCN1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.44
HRH2 P25021 9/20 0.43
HRH1 P35367 9/20 0.43
USP2 O75604 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TLR8 Q9NR97 1/20 0.43
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ACKR3 P25106 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13171609 0.91 USP2 (0.45) EPHX2USP2SMN1; SMN2TLR8CHRM2
SCHEMBL28710559 0.86 MEN1 (0.43) EPHX2USP2SMN1; SMN2TLR8CHRM2
SCHEMBL20873847 0.85 USP2 (0.53) EPHX2USP2SMN1; SMN2TLR8CHRM2
SCHEMBL16810242 0.84 EPHX2 (0.47) EPHX2HRH2HRH1USP2SMN1; SMN2
SCHEMBL470992 0.84 EPHX2 (0.47) EPHX2HRH2HRH1USP2SMN1; SMN2
SCHEMBL8253901 0.83 USP2 (0.51) EPHX2USP2SMN1; SMN2TLR8CHRM2
SCHEMBL22060030 0.82 USP2 (0.45) EPHX2USP2SMN1; SMN2TLR8CHRM2
SCHEMBL15217025 0.81 TLR8 (0.46) EPHX2HRH2HRH1USP2SMN1; SMN2
SCHEMBL13600638 0.81 USP2 (0.44) EPHX2USP2SMN1; SMN2TLR8CHRM2
SCHEMBL8242595 0.81 USP2 (0.61) EPHX2USP2SMN1; SMN2TLR8CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822448-B2 Pyrazoloquinoline compound ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-8822448-B2 Pyrazoloquinoline compound ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-20130225553-A1 PYRAZOLOQUINOLINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-08-29 US disclosed
US-20130225553-A1 PYRAZOLOQUINOLINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-08-29 US disclosed
WO-2012033144-A1 PYRAZOLOQUINOLINE COMPOUND アステラス製薬株式会社 (JP) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225553-A1 PYRAZOLOQUINOLINE COMPOUND PDE9A, PDE5A, PDE2A EPHX2 2729/4885HRH2 2709/4885HRH1 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.